ASCO GI: GLP-1 Receptor Agonist Use Linked to Reduced CRC Incidence
MONDAY, Jan. 12, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal cancer (CRC) incidence compared with aspirin, according to a study presented at the American Society of Clinical…
This GLP-1 mistake can make you gain weight 4 times faster than stopping diet and exercise
While GLP-1s boast impressive weight loss results, making one mistake could result in the pounds coming right back on, according to new research.
Ozempic made rapid weight loss easier. But here’s when keeping body fat is healthier, according to doctors
Back in the 2010s, celebrating bodies of all sizes was the rage. People magazine featured plus-size model Tess Holliday on the cover after her 2013 Instagram campaign #EffYourBeautyStandards went viral. Meghan Trainor’s pop hit ‘All About That Bass’ shared her momma’s advice to not worry about your size, while Lizzo celebrated her own body in […]
Tom Brady becomes ‘chief wellness officer’ at weight-loss shot company
The startup helps companies cover the high cost of GLP-1 drugs for employees
Novo Nordisk CEO Flags 1.5 Million US Users of Compounded GLP-1 Drugs
Jan 12 (Reuters) – Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions…
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs – Reuters
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs Reuters
IJMS, Vol. 27, Pages 759: A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms
IJMS, Vol. 27, Pages 759: A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms International Journal of Molecular Sciences doi: 10.3390/ijms27020759 Authors: Charalampos Voros Fotios Chatzinikolaou Ioannis Papapanagiotou Spyridon Polykalas Despoina Mavrogianni Aristotelis-Marios Koulakmanidis Diamantis Athanasiou Vasiliki Kanaka Kyriakos Bananis Antonia Athanasiou Aikaterini Athanasiou Georgios Papadimas […]
The hidden health risk of taking weight loss drugs – and what to do about it
A recent review found that many people taking GLP-1 drugs receive little or no meaningful nutrition advice
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Viking)…
What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients
GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting “GLP-3s,” claiming they are taking obesity medications to the next level. GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite. The informal term “GLP-3” refers to a […]